About this report

The pharmaceutical industry is at a crossroads. Healthcare costs are climbing. Shifting patient demographics and federal policies are rewriting the rules of engagement. Meanwhile, provider consolidation and evolving care delivery models are redefining how pharma companies engage with customers, influence prescribing habits, and ensure access to critical medications.

All of this is creating a more challenging operating environment, pushing pharma companies to rethink what it means to deliver value to healthcare stakeholders. Evidence generation is starting earlier in the product lifecycle.

Patient engagement is becoming a continuous priority. Product distribution is gaining ground as a strategic lever. Health systems are taking a broader view of product fit, considering operational impact and real-world outcomes. Emerging technologies like generative AI offer new possibilities to transform not just drug discovery, but also commercial enterprise operations — though they also demand thoughtful governance and integration. Together, these shifts call for a more adaptive, data-informed, and stakeholder-aware approach to commercial strategy.